Hereditary Cancers and Genetics

2021 ◽  
pp. 65-98
Author(s):  
Daniele Fanale ◽  
Laura Ottini ◽  
Enrico Ricevuto ◽  
Valerio Gristina ◽  
Valentina Calò ◽  
...  
Keyword(s):  
2019 ◽  
pp. 101-115 ◽  
Author(s):  
Lorenzo Ceppi ◽  
Don S. Dizon ◽  
Michael J. Birrer
Keyword(s):  

2000 ◽  
Vol 15 (4) ◽  
pp. 217-225 ◽  
Author(s):  
Deborah J. MacDonald ◽  
Mira Lessick

2017 ◽  
Author(s):  
Moloy T. Goswami ◽  
Daniel H. Hovelson ◽  
Anna Johnson ◽  
Scott A. Tomlins ◽  
Lucy Wang ◽  
...  
Keyword(s):  

2020 ◽  
Vol 6 (7) ◽  
pp. 559-568 ◽  
Author(s):  
Anup Kumar Singh ◽  
Xiaochun Yu

2020 ◽  
pp. 1-6
Author(s):  
Jude E. Cléophat ◽  
Sylvie Pelletier ◽  
Alberte Déry ◽  
Yann Joly ◽  
Pierre Gagnon ◽  
...  

Abstract Objective Palliative care providers may face questions from patients and relatives regarding the heritability of cancers. Implications of such discussions for providers have been little explored. This study aimed to gather palliative care providers’ views on their main needs, roles, and ethical concerns regarding cancer family history discussions. Method The palliative care providers who participated in the 2015 and 2017 annual meetings of the Quebec Palliative Care Association were approached to complete a web-based questionnaire. Study participants answered the questionnaire between November 2016 and July 2017. They were asked to identify the most facilitating factor for cancer family history discussions, as well as their most important knowledge needs, potential role, and ethical concerns. Descriptive analyses were conducted. Results Ninety-four palliative care providers answered the questionnaire. Access to specialized resources to obtain information and protocols or guidelines were considered the most facilitating factors for cancer family history discussions by 32% and 20% of providers, respectively. Knowledge of hereditary cancers was the most relevant educational need for 53%. Thirty-eight per cent considered essential to be informed about their rights and duties regarding cancer family history discussions. Being attentive to patients’ concerns and referring families to appropriate resources were identified as the most relevant roles for palliative care providers by 47% and 34% of respondents, respectively. Fifty-eight per cent agreed that cancer family history discussions should be initiated only if beneficial to family members. Significance of results Education on hereditary cancers made consensus among palliative care providers as the most important knowledge need regarding discussing cancer family history at the end of life. Nonetheless, other less commonly expressed needs, including access to genetics specialists, protocols, or guidelines, and awareness of provider rights and duties concerning such discussions, deserve attention. Answering providers’ needs might help optimize cancer predisposition management in palliative care.


2020 ◽  
Vol 21 (24) ◽  
pp. 9504
Author(s):  
Arisa Ueki ◽  
Akira Hirasawa

Hereditary gynecological cancers are caused by several inherited genes. Tumors that arise in the female reproductive system, such as ovaries and the uterus, overlap with hereditary cancers. Several hereditary cancer-related genes are important because they might lead to therapeutic targets. Treatment of hereditary cancers should be updated in line with the advent of various new methods of evaluation. Next-generation sequencing has led to rapid, economical genetic analyses that have prompted a concomitant and significant paradigm shift with respect to hereditary cancers. Molecular tumor profiling is an epochal method for determining therapeutic targets. Clinical treatment strategies are now being designed based on biomarkers based on tumor profiling. Furthermore, the National Comprehensive Cancer Network (NCCN) guidelines significantly changed the genetic testing process in 2020 to initially consider multi-gene panel (MGP) evaluation. Here, we reviewed the molecular features and clinical management of hereditary gynecological malignancies, such as hereditary breast and ovarian cancer (HBOC), and Lynch, Li–Fraumeni, Cowden, and Peutz–Jeghers syndromes. We also reviewed cancer-susceptible genes revealed by MGP tests.


Sign in / Sign up

Export Citation Format

Share Document